CA3022250A1 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride - Google Patents

Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Info

Publication number
CA3022250A1
CA3022250A1 CA3022250A CA3022250A CA3022250A1 CA 3022250 A1 CA3022250 A1 CA 3022250A1 CA 3022250 A CA3022250 A CA 3022250A CA 3022250 A CA3022250 A CA 3022250A CA 3022250 A1 CA3022250 A1 CA 3022250A1
Authority
CA
Canada
Prior art keywords
methyl
crystalline form
imidazo
methylpiperazin
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3022250A
Other languages
English (en)
French (fr)
Inventor
Christopher K. Murray
Leonard W. Rozamus
John J. Chaber
Pradeep Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Pharmaceuticals Inc
Original Assignee
Ariad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50929140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3022250(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharmaceuticals Inc filed Critical Ariad Pharmaceuticals Inc
Priority to CA3167093A priority Critical patent/CA3167093A1/en
Publication of CA3022250A1 publication Critical patent/CA3022250A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3022250A 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride Abandoned CA3022250A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3167093A CA3167093A1 (en) 2012-12-12 2013-05-09 Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261736543P 2012-12-12 2012-12-12
US61/736,543 2012-12-12
US201261737007P 2012-12-13 2012-12-13
US61/737,007 2012-12-13
US201361788208P 2013-03-15 2013-03-15
US61/788,208 2013-03-15
CA2815506A CA2815506C (en) 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2815506A Division CA2815506C (en) 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3167093A Division CA3167093A1 (en) 2012-12-12 2013-05-09 Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Publications (1)

Publication Number Publication Date
CA3022250A1 true CA3022250A1 (en) 2014-06-12

Family

ID=50929140

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3022250A Abandoned CA3022250A1 (en) 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
CA3167093A Pending CA3167093A1 (en) 2012-12-12 2013-05-09 Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
CA2815506A Active CA2815506C (en) 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3167093A Pending CA3167093A1 (en) 2012-12-12 2013-05-09 Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
CA2815506A Active CA2815506C (en) 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Country Status (9)

Country Link
US (9) US9493470B2 (enExample)
JP (5) JP6447508B2 (enExample)
CN (2) CN105188701A (enExample)
CA (3) CA3022250A1 (enExample)
CL (1) CL2015001643A1 (enExample)
HK (1) HK1218878A1 (enExample)
MX (11) MX391445B (enExample)
NZ (1) NZ709648A (enExample)
WO (2) WO2014093583A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034598B1 (ru) 2005-12-23 2020-02-25 Ариад Фармасьютикалз, Инк. Применение бициклических гетероарильных соединений для лечения рака
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA3022250A1 (en) * 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
EP3016954B1 (en) * 2013-07-04 2018-10-31 Sandoz AG Crystalline forms of ponatinib hydrochloride
CN104496995A (zh) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
EA201991197A1 (ru) * 2016-12-15 2020-01-13 Ариад Фармасьютикалз, Инк. БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
CA3067271A1 (en) 2017-06-20 2018-12-27 Apotex Inc. Crystalline forms of ponatinib hydrochloride
KR20250010134A (ko) * 2018-04-02 2025-01-20 스텔스 바이오테라퓨틱스 인코포레이티드 엘라미프레티드의 합성에 유용한 결정질 디펩티드
WO2019246479A1 (en) 2018-06-22 2019-12-26 Johnson Matthey Public Limited Company Form of ponatinib
CR20210287A (es) 2018-11-01 2022-02-15 Syros Pharmaceuticals Inc Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099067A (en) 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
ATE298325T1 (de) * 1999-11-08 2005-07-15 Schering Corp Verfahren zur herstellung von n-(4-hydroxyphenyl)-n'-(4'-aminophenyl)-piperaz ne
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
TW200418466A (en) 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
PE20051046A1 (es) 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
US20090131651A1 (en) * 2003-12-05 2009-05-21 Giles Albert Brown Synthesis of 2-substituted adenosines
DE602004018193D1 (de) 2003-12-24 2009-01-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
ATE402705T1 (de) 2003-12-24 2008-08-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
KR101194968B1 (ko) 2004-04-07 2012-10-25 메르크 세로노 에스.에이. Ｐｔｐ 1-ｂ 저해제로서의 1,1’-(1,2-에틴디일)비스-벤젠유도체
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
JP2008534565A (ja) 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Ｔｉｅ２阻害活性のあるアミノピリミジン誘導体
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
JP5321061B2 (ja) 2005-08-11 2013-10-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 不飽和複素環誘導体
EA034598B1 (ru) 2005-12-23 2020-02-25 Ариад Фармасьютикалз, Инк. Применение бициклических гетероарильных соединений для лечения рака
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila
CN103435595A (zh) 2006-05-08 2013-12-11 阿里亚德医药股份有限公司 炔类杂芳基化合物
US8278307B2 (en) 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
US20100273772A1 (en) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
US8329724B2 (en) * 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013509444A (ja) * 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
MX2013011589A (es) 2011-04-07 2013-12-16 Ariad Pharma Inc Metodos y composiciones para tratar enfermedad de parkinson.
KR20140022063A (ko) 2011-04-07 2014-02-21 어리어드 파마슈티칼스, 인코포레이티드 신경 변성 질환을 치료하기 위한 방법 및 조성물
US20150105377A1 (en) 2012-04-25 2015-04-16 Ariad Pharmaceuticals, Inc. Methods and Compositions for RAF Kinase Mediated Diseases
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
US20210024527A1 (en) 2021-01-28
US20210277011A1 (en) 2021-09-09
US9493470B2 (en) 2016-11-15
MX2021002258A (es) 2021-05-27
JP2016503010A (ja) 2016-02-01
MX2021002261A (es) 2021-05-27
JP7042175B2 (ja) 2022-03-25
MX359147B (es) 2018-09-17
US20210277012A1 (en) 2021-09-09
NZ709648A (en) 2020-05-29
JP2026010061A (ja) 2026-01-21
HK1218878A1 (zh) 2017-03-17
WO2014093579A2 (en) 2014-06-19
US11279705B2 (en) 2022-03-22
US20210277010A1 (en) 2021-09-09
WO2014093583A3 (en) 2014-08-07
US11192896B2 (en) 2021-12-07
MX2021002253A (es) 2021-05-27
JP7352841B2 (ja) 2023-09-29
JP2018168191A (ja) 2018-11-01
MX2021002255A (es) 2021-05-27
CA2815506C (en) 2018-12-11
WO2014093579A3 (en) 2014-07-10
CA3167093A1 (en) 2014-06-12
WO2014093583A2 (en) 2014-06-19
MX2021002259A (es) 2021-05-27
CN115043843A (zh) 2022-09-13
JP2022037122A (ja) 2022-03-08
US20190169196A1 (en) 2019-06-06
MX2021002254A (es) 2021-05-27
MX2021002264A (es) 2021-05-27
US10662197B2 (en) 2020-05-26
US10125136B2 (en) 2018-11-13
US20210340149A1 (en) 2021-11-04
US11384086B2 (en) 2022-07-12
MX391445B (es) 2025-03-21
MX2021002257A (es) 2021-05-27
JP6447508B2 (ja) 2019-01-09
CL2015001643A1 (es) 2015-10-02
US11192895B2 (en) 2021-12-07
JP2023179498A (ja) 2023-12-19
MX2021002256A (es) 2021-05-27
US20240083902A1 (en) 2024-03-14
US20150315194A1 (en) 2015-11-05
CA2815506A1 (en) 2014-06-12
US20170190707A1 (en) 2017-07-06
US11192897B2 (en) 2021-12-07
MX2015007578A (es) 2016-03-21
CN105188701A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
US20240083902A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
AU2018244451A1 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide
AU2023219845B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N- {4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
HK40080449A (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
EA044397B1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-(ЦИКЛОПРОПАНКАРБОКСАМИДО)-4-((2-МЕТОКСИ-3-(1-МЕТИЛ-1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ФЕНИЛ)АМИНО)-N-(МЕТИЛ-d3)ПИРИДАЗИН-3-КАРБОКСАМИДА

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190426

FZDE Discontinued

Effective date: 20220711